Pfizer has agreed to acquire Metsera for $10 billion, outbidding Novo Nordisk in a heated competition. Metsera’s board unanimously approved Pfizer’s improved offer, citing significant legal and regulatory risks associated with the Novo Nordisk proposal. This acquisition highlights the intense race among pharmaceutical giants for a share of the booming global obesity and diabetes treatment market.